|
Introduction
of Benserazide
Benserazide is an inhibitor of DOPA decarboxylase that does
not enter the central nervous system. Benserazide is often
given in combination with L-DOPA (levodopa) as Co-Beneldopa
(BAN) (e.g. MadoparŪ by Roche in UK) in the treatment of
Parkinson's disease to prevent the conversion of L-DOPA to
dopamine in the periphery (due to its molecular size it can
not penetrate the blood brain barrier) the amount that
reaches the central nervous system and reducing the required
dose, and also decreasing side effects due to the presence
of dopamine in the system (outside of the central nervous
system). Benserazide has no antiparkinson actions when given
alone.
Disclaimer:
Information on this page is provided for general
information purposes. You should not make a clinical treatment
decision based on information contained in this page without
consulting other references including the package insert of
the drug, textbooks and where relevant, expert opinion. We
cannot be held responsible for any errors you make in
administering drugs mentioned on this page, nor for use of any
erroneous information contained on this page.
|
